{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"22.2","upperLimit":"46.7","value":"0"}]}],"title":"Complete Response (CR)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"near Complete Response(nCR)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"18"}]}],"title":"Partial Response (PR)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"10"}]}],"title":"Minimal Response (MR)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"20"}]}],"title":"No Change"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"Pregressive Disease (PD)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"Unknown"}],"denoms":[{"counts":[{"groupId":"OG000","value":"55"}],"units":"Participants"}],"description":"The primary endpoint for this phase II study of patients with bortezomib-refractory MM is response after a maximum of 8 cycles of therapy as defined by the modified EBMT criteria.","groups":[{"description":"panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory multiple myeloma","id":"OG000","title":"Panobinostat + Bortezomib & Dexamethasone"}],"paramType":"NUMBER","populationDescription":"Full Analysis Set","reportingStatus":"POSTED","timeFrame":"after eight cycyles of treatment (24 weeks)","title":"Responders to Treatment","type":"SECONDARY","unitOfMeasure":"participants"}